Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 18

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 3
Chunk 18
---
 wars, through the implementation of tariffs or otherwise, could materially and adversely affect us, directly and indirectly, including by adversely impacting the supply chains for our operations, and increasing the costs of services we provide and utilize. For example, a majority of our revenue is generated in the United States under the supply and distribution agreement with Symrise AG and such revenue could become subject to tariffs for goods being imported from Canada. Additionally, our importation of raw materials, such as high-quality oats used in our avenanthramide products, could become subject to retaliatory tariffs imposed by Canadian authorities on goods imported from the United States.
 
Moreover, the change in presidential administration, as well as a transition of control in the House of Representatives and United States Senate, creates regulatory uncertainty and it remains unclear as to what specifically the current presidential administration would or would not do with respect to certain programs and initiatives.
 

17
--
 

If our products do not gain broad market acceptance, we may be unable to generate significant revenues.
 
Our revenues largely depend on sales of our oat-based pipeline products under our supply and distribution agreement with Symrise AG. Broad market acceptance of our products, including our oat-based pipeline products and Macrilen™ (macimorelin), depends on a number of factors, including, but not limited to, the following:
 

●           demonstration of clinical efficacy and safety of our products;       
---------------------------------------------------------------------------------
●   the prevalence and severity of any adverse side effects related to           
    our products;                                                                
●   limitations or warnings contained in our products’ approved labeling;        
●   availability of alternative market offerings for our products;               
●   the advantages and disadvantages of our products relative to current         
    or alternative market offerings;                                             
●   the classification and description of our products in relevant guidelines;   
●   our ability to diversify of customer base outside of the Symrise AG          
    distribution arrangement;                                                    
●   our ability to develop and effectively market new products;                  
●   the availability of acceptable pricing and adequate third-party reimbursement
    for our products, as applicable; and                                         
●   the effectiveness of marketing and distribution methods for our products.    
 
If our products do not gain market acceptance outside of the Symrise AG distribution arrangement, our ability to generate significant revenues would be limited, and our financial condition could be materially, adversely affected. In addition, if we fail to further penetrate our core markets and existing geographic markets or to successfully expand our business into new markets, the growth in sales of our products, along